Akwa Ibom State Government, in collaboration with the World Health Organization (WHO), has unveiled a long-acting injectable drug for HIV prevention, marking a significant step in strengthening Nigeria’s public health response to HIV/AIDS.
The new injectable, known as Lenacapavir, is a pre-exposure prophylaxis (PrEP) option designed to offer longer-lasting protection against HIV infection compared to traditional daily oral medication.
Health authorities say the innovation is part of broader efforts to expand access to modern, effective, and user-friendly HIV prevention tools, particularly for high-risk and vulnerable populations.
The development aligns with Nigeria’s ongoing commitment to reducing new HIV infections and advancing toward global targets for ending AIDS as a public health threat by 2030.
Experts note that long-acting injectable PrEP could improve adherence, reduce stigma associated with daily medication, and strengthen prevention outcomes across communities.
The rollout is being supported by international partners, including WHO and global health initiatives, as part of a coordinated strategy to scale up HIV prevention services across priority states in Nigeria.
The Sun Nigeria reports that the initiative reflects a growing shift toward innovative, science-driven approaches in the country’s HIV response.
English